drugset

drugset / Trial / NCT00939783

An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

NCT00939783 ↗

Phase 3 Terminated 649 enrolled Pfizer Medivation, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.

Timeline

Start: 2009-09
Primary completion: 2010-08
Completion: 2010-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latrepirdine	Small molecule	20 mg	Oral

Indications